Apollomics (NASDAQ:APLM) CFO Acquires $400,005.00 in Stock

Apollomics Inc. (NASDAQ:APLM) CFO Peter Kuan-How Lin purchased 26,667 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $400,005.00. Following the purchase, the chief financial officer directly owned 48,979 shares of the company’s stock, valued at approximately $734,685. The trade was a 119.52% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Apollomics Stock Performance

APLM opened at $23.70 on Thursday. The firm’s 50-day moving average price is $18.63 and its 200-day moving average price is $17.38. Apollomics Inc. has a 52-week low of $3.66 and a 52-week high of $42.12.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new position in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is currently owned by institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.